

RegMedinvestors

On-demand news, analysis and synthesis

Defining the who, where, when, why, and what of it

For five (5) years, RegMed Investors (RMI) has provided up-to-the-minute news, analysis, and actionable direction on companies and developments in the sector. Our commitment to objectivity means our readers can trust the perspective we offer in this complex sector and the equities within.

The offering

It's simple, synthesis! I analyze this sector, dissecting its claims by separating fact from science fiction through myriad approaches:

- RMI's comprehensive content driven news portal combines equity research, detailed diligence, skepticism, interpretation of trading cycles expectation versus anticipation, and objectivity;
- Henry'omics – a favorite of many readers, a “neologism” as the ‘omics refers to my OBJECTIVE reaction in a RegMed universe event. The related suffix -ome is used to address my objects of study in the stem and cell therapy and regenerative medicine field.
- News reviews that keep clients on top of the actionable intelligence that transforms the stem and cell therapy and RegMed universe to “surface” risks and opportunities not already priced into the marketplace.
- “Clear and Present Dangers” that bring to life the levels of executive compensation, salary, bonus, options, grants, payments for board participation and other bennies or reimbursed factors that investors have a RIGHT to ... KNOW!
- Indicators of insider holdings or “skin-in-the-game” that relate to management's ownership defining belief, motivations and ability of any sector participant's security that's also is a signal, cue or even a prompt or call to action as investors review ... whether to act on an investment;
- Short Selling -- a not so subtle "borrowed" position that reflects and detects changes in traders and investor's behaviors during the assessment of an equity position.
- If these aren't enough... IP/Patent updates, BOD changes, and executive buying/selling moves, etc.

What's the price and where is it going?

Something that should be appreciated by investors in companies and outside the investment world. RMI creates value by providing facts, first and fast, based on vetted information and analyzed data. Investors crave more than "I-Bank recommendations" or their analysts' "compromised view" – that must be chewed, and then spit!

The #1 Choice of RegMed Industry Leaders

RMI doesn't deliver traditional plain vanilla research notes that feature "time-lapsed" recommendations strewn with I-Bank caveats. Instead, we champion a "high and tight" synthesis that identifies value to corresponding events; explaining their meaning while measuring impact in the market to the pricing of the event and its effect upon valuation.

What I understand is the short, near and long term potential of stem and cell therapy companies fulfilling milestones and reaching established goals. I don't try to out science the scientist or even co-opt the management. But I do render an opinion based on evidentiary facts and realities!

Phone: 617.559.1080

www.regmedinvestors.com